Bevasiranib

Drug Profile

Bevasiranib

Alternative Names: Bevasiranib sodium; Cand 5

Latest Information Update: 05 Nov 2014

Price : $50

At a glance

  • Originator Opko Health
  • Developer OPKO Health
  • Class Eye disorder therapies; Small interfering RNA
  • Mechanism of Action RNA interference; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration

Most Recent Events

  • 07 Mar 2009 Discontinued - Phase-III for Age-related macular degeneration in Canada (Intravitreous)
  • 07 Mar 2009 Discontinued - Phase-III for Age-related macular degeneration in USA (Intravitreous)
  • 08 Dec 2008 OPKO Health completes enrolment in the phase III COBALT trial for Age-related macular degeneration in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top